Kesimpta (Ofatumumab)

Ofatumumab is a monoclonal antibody that binds to the CD20 protein on mature B‑cells. This binding activates complement and immune effector mechanisms, leading to rapid B‑cell depletion. By reducing the number of circulating B‑cells, the drug diminishes the immune‑mediated inflammation that drives multiple sclerosis lesions.

The dosing regimen for Kesimpta is determined by the prescribing healthcare professional based on the approved label and individual patient factors. Patients receive a subcutaneous injection according to the schedule set by their neurologist or specialist; exact amounts and intervals are not disclosed here.

Data on the use of Kesimpta in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider, who can weigh disease control against any possible fetal or infant exposure.

To request Kesimpta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and necessary import documentation.

Kesimpta belongs to the CD20‑directed monoclonal antibody class, similar to ocrelizumab, but is administered subcutaneously rather than intravenously. Compared with oral agents such as dimethyl fumarate or fingolimod, Kesimpta offers a targeted B‑cell approach with a different safety profile, including a lower infusion‑related reaction risk but a need for infection monitoring.

Kesimpta must be stored in a refrigerator at 2‑8 °C (36‑46 °F). It should be kept in its original packaging, protected from light, and must not be frozen or shaken. If the product is inadvertently exposed to temperatures outside this range, it should be discarded according to the supplier’s guidelines.

Kesimpta is supplied as a solution for subcutaneous injection. After appropriate training, patients or caregivers can self‑administer the injection into the abdomen or thigh using the pre‑filled device. The first dose is usually given in a clinical setting to monitor for any immediate reactions, after which subsequent doses can be taken at home according to the prescribed schedule.

The most serious risks include severe infections such as pneumonia, reactivation of hepatitis B virus, and rare cases of progressive multifocal leukoencephalopathy (PML). Patients should promptly report fever, persistent cough, unexplained fatigue, or any signs of liver dysfunction, and clinicians should regularly monitor liver function and viral status.

Kesimpta is contraindicated in individuals with known hypersensitivity to ofatumumab or any of its excipients. It should also be avoided in patients with active, severe infections, uncontrolled hepatitis B infection, or severe immunodeficiency. Clinicians must evaluate each patient’s medical history before initiating therapy.